Synthesis and Biological Evaluation of Small Molecule Inhibitors of Immune Cytopenias
Open Access
- 25 July 2025
- journal article
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 10 (30) , 33401-33414
Abstract
Immune cytopenias are a group of autoimmune disorders where patients develop autoantibodies against certain types of blood cells such as red blood cells (RBCs) or thrombocytes. We investigated small molecules as potential inhibitors of phagocytosis of blood cells that are prevalent in immune thrombocytopenia (ITP) and warm autoantibody immune hemolytic anemia (wAIHA). Upon screening a chemical library of over 13,000 compounds in silico, followed by evaluating 80 compounds in vitro as inhibitors of phagocytosis of opsonized RBCs by monocytes, we identified four hit molecules. These compounds contain a pyrazole moiety as a key structural feature. Here, we reveal the independent synthesis and re-evaluation of these hits, as well as revalidate the biological activities and the synthesis of their analogs to understand the structure–activity relationships. Two of the resynthesized compounds showed up to a 9-fold difference in their inhibitory activities between the commercial and synthesized batches, and the analogs exhibited either equal or weaker potency than the parent compounds targeting phagocytosis of RBCs. The role of regioisomers and the importance of an ester moiety are revealed as important structural features through these analogs. The pharmacokinetics of the promising compound 33 suggested that this compound shows significant efficacy in restoring platelet counts in the mouse model of ITP, despite the rapid hydrolysis of its methyl ester moiety.Keywords
Funding Information
- Canadian Blood Services (XT00136)
This publication has 50 references indexed in Scilit:
- Sialylation‐independent mechanism involved in the amelioration of murine immune thrombocytopenia using intravenous gammaglobulinTransfusion, 2012
- An l-proline functionalized metallo-organic triangle as size-selective homogeneous catalyst for asymmetry catalyzing aldol reactionsChemical Communications, 2011
- Improved mouse models for the study of treatment modalities for immune‐mediated platelet destructionTransfusion, 2010
- A murine model of severe immune thrombocytopenia is induced by antibody- and CD8+ T cell–mediated responses that are differentially sensitive to therapyBlood, 2010
- Discovery of 1-[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea (Nelotanserin) and Related 5-Hydroxytryptamine2AInverse Agonists for the Treatment of InsomniaJournal of Medicinal Chemistry, 2010
- Response to B-cell–depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpuraBlood, 2007
- Can antibodies with specificity for soluble antigens mimic the therapeutic effects of intravenous IgG in the treatment of autoimmune disease?Journal of Clinical Investigation, 2005
- Autoantibodies and autoantigens in chronic immune thrombocytopenic purpuraSeminars in Hematology, 2000
- Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology.1996
- Physiological regulation of early and late stages of megakaryocytopoiesis by thrombopoietin.Journal of Experimental Medicine, 1996